Dr. Gordon B. Mills on Moving Toward Patient-Specific Treatment in Breast Cancer

Video

​Gordon B. Mills, MD, PhD, says individualized treatment, as opposed to treating patients solely based on their malignancy type, must happen in order to improve patient outcome.

Gordon B. Mills, MD, PhD, chair of Systems Biology, co-director of the Institute of Personalized Medicine, University of Texas MD Anderson Cancer Center, discusses the oncological trend of moving toward individually treating patients with breast cancer. Mills says this individualized treatment, as opposed to treating patients solely based on their malignancy type, must happen in order to improve patient outcome.

Related Videos
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Video 4 - "KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer"
Video 3 - "APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer"
Rebecca A. Shatsky, MD, an expert on breast cancer
Rebecca A. Shatsky, MD, an expert on breast cancer
Related Content